Influence of rifampicin on the pharmacokinetics of salvianolic acid b may involve inhibition of organic anion transporting polypeptide (Oatp) mediated influx

Phytotherapy Research

Volumn 26, Issue 1, 2012, Pages 118-121

  Zhao, Di ^a   Gao, Zi Dong ^a   Han, De En ^a   Li, Ning ^a   Zhang, Yong Jie ^a   Lu, Yang ^a   Li, Ting Ting ^a   Chen, Xi Jing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

drug herb interaction; organic anion transporting polypeptide (Oatp); pharmacokinetics; rifampicin (RIF); salvianolic acid B (SAB)

Indexed keywords

ORGANIC ANION TRANSPORTER; RIFAMPICIN; SALVIANOLIC ACID B;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; BENZOFURANS; BILE; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; ENZYME INHIBITORS; HERB-DRUG INTERACTIONS; MALE; MASS SPECTROMETRY; ORGANIC ANION TRANSPORTERS; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; SALVIA MILTIORRHIZA;

RATTUS;

EID: 84855687423     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3522     Document Type: Article

References (23)

1. Chan TY,. 2001. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother 35: 501-504. (Pubitemid 32260218)
2. Chen C, Stock JL, Liu X, et al,. 2008. Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug Metab Dispos 36: 1840-1845.
3. Chen YF, Jaw I, Shiao MS, Tsai TH,. 2005. Determination and pharmacokinetic analysis of salvianolic acid B in rat blood and bile by microdialysis and liquid chromatography. J Chromatogr A 1088: 140-145. (Pubitemid 41058812)
4. Fromm MF, Kauffmann HM, Fritz P, et al,. 2000. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157: 1575-1580.
5. Greiner B, Eichelbaum M, Fritz P, et al,. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104: 147-153.
6. Lam JL, Shugarts SB, Okochi H, Benet LZ,. 2006. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther 319: 864-870.
7. Lau YY, Okochi H, Huang Y, Benet LZ,. 2006. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34: 1175-1181.
8. Lau YY, Wu CY, Okochi H, Benet LZ,. 2004. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 308: 1040-1045. (Pubitemid 38263980)
9. Li M, Zhao C, Wong RN,. 2004. Inhibition of shear-induced platelet aggregation in rat by tetramethylpyrazine and Sal B. Clin Hemorheol Micro 31: 97-103. (Pubitemid 39273876)
10. Liu P, Hu YY, Liu C,. 2002. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 8: 679-685. (Pubitemid 34918663)
11. Ma L, Ren WC, Dong J, He H, Chen XJ, Wang GJ,. 2007. Pharmacokinetics of salvianolic acid B after intravenous administration in rats. Chin J Clin Pharmacol Ther 12: 1231-1236.
12. Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M,. 2007. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther 32: 161-167. (Pubitemid 46449707)
13. Mallolas J, Sarasa M, Nomdedeu M, et al,. 2007. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 8: 131-134. (Pubitemid 46390850)
14. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT,. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42: 819-850. (Pubitemid 36995083)
15. Oswald S, Giessmann T, Luetjohann D, et al,. 2006. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 80: 477-485. (Pubitemid 44767877)
16. Ribera E, Azuaje C, Lopez RM, et al,. 2007. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 59: 690-697. (Pubitemid 47073403)
17. Sekine T, Miyazaki H, Endou H,. 2006. Molecular physiology of renal organic anion transporters. Am J Physiol Ren Physiol 290: 251-261.
18. Shiao MS, Chiu JJ, Chang BW, et al,. 2008. In search of antioxidants and anti-atherosclerotic agents from herbal medicines. Biofactors 34: 147-157.
19. Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD,. 2001. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 29: 1467-1472. (Pubitemid 33000694)
20. Tirona RG, Leake BF, Wolkoff AW, Kim RB,. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304: 223-228. (Pubitemid 36008932)
21. Treiber A, Schneiter R, Hǧusler S, Stieger B,. 2007. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35: 1400-1407. (Pubitemid 47121782)
22. Yasuda K, Ranade A, Venkataramanan R, et al,. 2008. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos 36: 1689-1697.
23. Zaher H, zu Schwabedissen HE, Tirona RG, et al,. 2008. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74: 320-329.